Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae …

MM Sfeir, G Askin, P Christos - International journal of antimicrobial agents, 2018 - Elsevier
Background Infections due to extended-spectrum beta-lactamase (ESBL)-producing
Enterobacteriaceae pose a major public health threat due to poor outcomes and high …
被引用次数：60 相关文章

Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae …

MM Sfeir, G Askin, P Christos - 2018 - cabidigitallibrary.org
Background: Infections due to extended-spectrum beta-lactamase (ESBL)-producing
Enterobacteriaceae pose a major public health threat due to poor outcomes and high …

Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae …

MM Sfeir, G Askin, P Christos - International journal of …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Infections due to extended-spectrum beta-lactamase (ESBL)-producing
Enterobacteriaceae pose a major public health threat due to poor outcomes and high …

Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae …

MM Sfeir, G Askin, P Christos - International Journal of Antimicrobial …, 2018 - europepmc.org
Background Infections due to extended-spectrum beta-lactamase (ESBL)-producing
Enterobacteriaceae pose a major public health threat due to poor outcomes and high …

[引用][C] Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended spectrum beta-lactamase producing Enterobacteriaceae …

M Sfeir, G Askin, P Christos - 2018